Chemo plus radiation for advanced pancreatic cancer with normal CA19-9
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a strong chemotherapy combination (mFOLFIRINOX) together with radiation therapy can help people with advanced pancreatic cancer who have normal CA19-9 levels. It aims to see if this approach is more effective for this specific group of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have been diagnosed with advanced pancreatic cancer (adenocarcinoma type) and have not had any treatment for it yet.
- Your blood tests show normal levels of CA19-9 (a tumor marker), CEA, and CA125.
- You have at least one tumor that can be seen on imaging (like a CT scan).
- You are generally in good enough health (ECOG score 0-2) and your organs are working well enough for treatment.
- You are willing to use birth control if needed, and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving radiotherapy to the pancreas can help people with advanced pancreatic cancer whose CA19-9 level has dropped to normal after chemotherapy. It's for patients whose cancer is still locally advanced (hasn't spread to distant organs).
This trial tests combining endoscopic ultrasound-guided radiofrequency ablation with FOLFIRINOX chemotherapy for people with advanced pancreatic cancer that hasn't spread to other organs. It aims to see if this approach is safe and effective.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests a new combination of two experimental drugs (9-ING-41 and retifanlimab) plus a standard chemotherapy regimen (modified FOLFIRINOX) for people with advanced or metastatic pancreatic cancer who have not yet received treatment for their advanced disease. The goal is to see if this combination is safe and effective.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of chemotherapy (mFOLFIRINOX) and radiation therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy and whose CA19-9 tumor marker levels are normal. The goal is to see if this approach can help when standard treatments are no longer working.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.